Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial

IF 32.8 1区 医学 Q1 CRITICAL CARE MEDICINE
Carlos Ferrando, Albert Carramiñana, Patricia Piñeiro, Lucia Mirabella, Savino Spadaro, Julián Librero, Fernando Ramasco, Gaetano Scaramuzzo, Oriol Cervantes, Ignacio Garutti, Ana Parera, Marta Argilaga, Gracia Herranz, Carmen Unzueta, Marc Vives, Kevin Regi, Marta Costa-Reverte, María Sonsoles Leal, Jesús Nieves-Alonso, Esther García, Stefania Spiga
{"title":"Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial","authors":"Carlos Ferrando, Albert Carramiñana, Patricia Piñeiro, Lucia Mirabella, Savino Spadaro, Julián Librero, Fernando Ramasco, Gaetano Scaramuzzo, Oriol Cervantes, Ignacio Garutti, Ana Parera, Marta Argilaga, Gracia Herranz, Carmen Unzueta, Marc Vives, Kevin Regi, Marta Costa-Reverte, María Sonsoles Leal, Jesús Nieves-Alonso, Esther García, Stefania Spiga","doi":"10.1016/s2213-2600(23)00346-6","DOIUrl":null,"url":null,"abstract":"<h3>Background</h3><p><span>It is uncertain whether individualisation of the perioperative open-lung approach (OLA) to ventilation reduces postoperative pulmonary complications </span>in patients<span> undergoing lung resection<span>. We compared a perioperative individualised OLA (iOLA) ventilation strategy with standard lung-protective ventilation in patients undergoing thoracic surgery with one-lung ventilation.</span></span></p><h3>Methods</h3><p><span>This multicentre, randomised controlled trial<span> enrolled patients scheduled for open or video-assisted thoracic surgery using one-lung ventilation in 25 participating hospitals in Spain, Italy, Turkey, Egypt, and Ecuador. Eligible adult patients (age ≥18 years) were randomly assigned to receive iOLA or standard lung-protective ventilation. Eligible patients (stratified by centre) were randomly assigned online by local principal investigators, with an allocation ratio of 1:1. Treatment with iOLA included an alveolar recruitment manoeuvre to 40 cm H</span></span><sub>2</sub><span>O of end-inspiratory pressure followed by individualised positive end-expiratory pressure (PEEP) titrated to best respiratory system compliance, and individualised postoperative respiratory support with high-flow oxygen therapy. Participants allocated to standard lung-protective ventilation received combined intraoperative 4 cm H</span><sub>2</sub><span><span>O of PEEP and postoperative conventional oxygen therapy. The primary outcome was a composite of severe postoperative pulmonary complications within the first 7 postoperative days, including atelectasis<span> requiring bronchoscopy, severe respiratory failure, </span></span>contralateral<span><span><span> pneumothorax<span><span>, early extubation failure (rescue with continuous positive airway pressure, non-invasive ventilation, invasive </span>mechanical ventilation, or reintubation), </span></span>acute respiratory distress syndrome, pulmonary infection, </span>bronchopleural fistula<span>, and pleural empyema. Due to trial setting, data obtained in the operating and postoperative rooms for routine monitoring were not blinded. At 24 h, data were acquired by an investigator blinded to group allocation. All analyses were performed on an intention-to-treat basis. This trial is registered with </span></span></span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"8px\" viewbox=\"0 0 8 8\" width=\"8px\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg>, <span>NCT03182062</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"8px\" viewbox=\"0 0 8 8\" width=\"8px\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg>, and is complete.</p><h3>Findings</h3><p>Between Sept 11, 2018, and June 14, 2022, we enrolled 1380 patients, of whom 1308 eligible patients (670 [434 male, 233 female, and three with missing data] assigned to iOLA and 638 [395 male, 237 female, and six with missing data] to standard lung-protective ventilation) were included in the final analysis. The proportion of patients with the composite outcome of severe postoperative pulmonary complications within the first 7 postoperative days was lower in the iOLA group compared with the standard lung-protective ventilation group (40 [6%] <em>vs</em> 97 [15%], relative risk 0·39 [95% CI 0·28 to 0·56]), with an absolute risk difference of –9·23 (95% CI –12·55 to –5·92). Recruitment manoeuvre-related adverse events were reported in five patients.</p><h3>Interpretation</h3><p>Among patients subjected to lung resection under one-lung ventilation, iOLA was associated with a reduced risk of severe postoperative pulmonary complications when compared with conventional lung-protective ventilation.</p><h3>Funding</h3><p>Instituto de Salud Carlos III and the European Regional Development Funds.</p>","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":" 2","pages":""},"PeriodicalIF":32.8000,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2213-2600(23)00346-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 1

Abstract

Background

It is uncertain whether individualisation of the perioperative open-lung approach (OLA) to ventilation reduces postoperative pulmonary complications in patients undergoing lung resection. We compared a perioperative individualised OLA (iOLA) ventilation strategy with standard lung-protective ventilation in patients undergoing thoracic surgery with one-lung ventilation.

Methods

This multicentre, randomised controlled trial enrolled patients scheduled for open or video-assisted thoracic surgery using one-lung ventilation in 25 participating hospitals in Spain, Italy, Turkey, Egypt, and Ecuador. Eligible adult patients (age ≥18 years) were randomly assigned to receive iOLA or standard lung-protective ventilation. Eligible patients (stratified by centre) were randomly assigned online by local principal investigators, with an allocation ratio of 1:1. Treatment with iOLA included an alveolar recruitment manoeuvre to 40 cm H2O of end-inspiratory pressure followed by individualised positive end-expiratory pressure (PEEP) titrated to best respiratory system compliance, and individualised postoperative respiratory support with high-flow oxygen therapy. Participants allocated to standard lung-protective ventilation received combined intraoperative 4 cm H2O of PEEP and postoperative conventional oxygen therapy. The primary outcome was a composite of severe postoperative pulmonary complications within the first 7 postoperative days, including atelectasis requiring bronchoscopy, severe respiratory failure, contralateral pneumothorax, early extubation failure (rescue with continuous positive airway pressure, non-invasive ventilation, invasive mechanical ventilation, or reintubation), acute respiratory distress syndrome, pulmonary infection, bronchopleural fistula, and pleural empyema. Due to trial setting, data obtained in the operating and postoperative rooms for routine monitoring were not blinded. At 24 h, data were acquired by an investigator blinded to group allocation. All analyses were performed on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, NCT03182062, and is complete.

Findings

Between Sept 11, 2018, and June 14, 2022, we enrolled 1380 patients, of whom 1308 eligible patients (670 [434 male, 233 female, and three with missing data] assigned to iOLA and 638 [395 male, 237 female, and six with missing data] to standard lung-protective ventilation) were included in the final analysis. The proportion of patients with the composite outcome of severe postoperative pulmonary complications within the first 7 postoperative days was lower in the iOLA group compared with the standard lung-protective ventilation group (40 [6%] vs 97 [15%], relative risk 0·39 [95% CI 0·28 to 0·56]), with an absolute risk difference of –9·23 (95% CI –12·55 to –5·92). Recruitment manoeuvre-related adverse events were reported in five patients.

Interpretation

Among patients subjected to lung resection under one-lung ventilation, iOLA was associated with a reduced risk of severe postoperative pulmonary complications when compared with conventional lung-protective ventilation.

Funding

Instituto de Salud Carlos III and the European Regional Development Funds.

单肺通气期间个体化围手术期开肺通气策略(iPROVE-OLV):一项多中心、随机、对照临床试验
目前尚不清楚围手术期开肺入路(OLA)通气的个体化是否能减少肺切除术患者的术后肺部并发症。我们比较了围手术期个体化OLA (iOLA)通气策略与标准肺保护性通气在接受单肺通气胸外科手术患者中的应用。方法本多中心随机对照试验纳入了西班牙、意大利、土耳其、埃及和厄瓜多尔25家参与试验的医院中计划采用单肺通气进行开放或视频辅助胸外科手术的患者。符合条件的成年患者(年龄≥18岁)被随机分配接受iOLA或标准肺保护通气。符合条件的患者(按中心分层)由当地主要研究者在线随机分配,分配比例为1:1。iOLA治疗包括肺泡恢复操作至40 cm H2O的吸气末压力,然后个体化呼气末正压(PEEP)滴定至最佳呼吸系统顺应性,以及个体化术后高流量氧治疗呼吸支持。标准肺保护通气组患者术中4 cm H2O PEEP与术后常规氧疗联合治疗。主要结局是术后前7天内严重的术后肺部并发症,包括需要支气管镜检查的肺不张、严重呼吸衰竭、对侧气胸、早期拔管失败(持续气道正压通气、无创通气、有创机械通气或重新插管)、急性呼吸窘迫综合征、肺部感染、支气管胸膜瘘和胸膜脓胸。由于试验设置,在手术室和术后常规监测中获得的数据没有盲法。24小时时,由一名不知道分组分配情况的研究者获取数据。所有分析均以意向治疗为基础进行。该试验已在ClinicalTrials.gov注册,编号NCT03182062,并且已经完成。在2018年9月11日至2022年6月14日期间,我们纳入了1380名患者,其中1308名符合条件的患者(670名[434名男性,233名女性,3名数据缺失]被分配到iOLA, 638名[395名男性,237名女性,6名数据缺失]被分配到标准肺保护通气)被纳入最终分析。iOLA组术后前7天出现严重术后肺部并发症的患者比例低于标准肺保护通气组(40例[6%]vs 97例[15%],相对危险度0.39 [95% CI 0.28 ~ 0.56]),绝对危险度差为- 9.23 (95% CI - 12.55 ~ - 5.92)。在5例患者中报告了招募操作相关的不良事件。在单肺通气下进行肺切除术的患者中,与常规肺保护性通气相比,iOLA与术后严重肺部并发症的风险降低相关。卡洛斯三世研究所和欧洲区域发展基金。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Lancet Respiratory Medicine
Lancet Respiratory Medicine RESPIRATORY SYSTEM-RESPIRATORY SYSTEM
CiteScore
87.10
自引率
0.70%
发文量
572
期刊介绍: The Lancet Respiratory Medicine is a renowned journal specializing in respiratory medicine and critical care. Our publication features original research that aims to advocate for change or shed light on clinical practices in the field. Additionally, we provide informative reviews on various topics related to respiratory medicine and critical care, ensuring a comprehensive coverage of the subject. The journal covers a wide range of topics including but not limited to asthma, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), tobacco control, intensive care medicine, lung cancer, cystic fibrosis, pneumonia, sarcoidosis, sepsis, mesothelioma, sleep medicine, thoracic and reconstructive surgery, tuberculosis, palliative medicine, influenza, pulmonary hypertension, pulmonary vascular disease, and respiratory infections. By encompassing such a broad spectrum of subjects, we strive to address the diverse needs and interests of our readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信